Zobrazeno 1 - 10
of 263
pro vyhledávání: '"Shu‐Qun Cheng"'
Autor:
Yu Yang, Juxian Sun, Jianqiang Cai, Minshan Chen, Chaoliu Dai, Tianfu Wen, Jinglin Xia, Mingang Ying, Zhiwei Zhang, Xuewen Zhang, Chihua Fang, Feng Shen, Ping An, Qingxian Cai, Jingyu Cao, Zhen Zeng, Gang Chen, Juan Chen, Ping Chen, Yongshun Chen, Yunfeng Shan, Shuangsuo Dang, Wei-Xing Guo, Jiefeng He, Heping Hu, Bin Huang, Weidong Jia, Kexiang Jiang, Yan Jin, Yongdong Jin, Yun Jin, Gong Li, Yun Liang, Enyu Liu, Hao Liu, Wei Peng, Zhenwei Peng, Zhiyi Peng, Yeben Qian, Wanhua Ren, Jie Shi, Yusheng Song, Min Tao, Jun Tie, Xueying Wan, Bin Wang, Jin Wang, Kai Wang, Kang Wang, Xin Wang, Wenjing Wei, Fei-Xiang Wu, Bangde Xiang, Lin Xie, Jianming Xu, Mao-Lin Yan, Yufu Ye, Jinbo Yue, Xiaoxun Zhang, Yu Zhang, Aibin Zhang, Haitao Zhao, Weifeng Zhao, Xin Zheng, Hongkun Zhou, Huabang Zhou, Jun Zhou, Xinmin Zhou, Shu-Qun Cheng, Qiu Li
Publikováno v:
Liver Cancer, Pp 1-1 (2024)
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complications of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatme
Externí odkaz:
https://doaj.org/article/e461e172d2b44ff2a14326f6d37231d6
Publikováno v:
Annals of Surgery Open, Vol 5, Iss 2, p e407 (2024)
Externí odkaz:
https://doaj.org/article/8dc4978d3296491a996c4ff7c300af07
Autor:
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Jin-Kai Feng, Zong-Han Liu, Yun-Feng Shan, Yi-Tao Zheng, Qian-Zhi Ni, Shu-Qun Cheng
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment durati
Externí odkaz:
https://doaj.org/article/28580eb814714c9bace2a2194c6774a8
Autor:
Hong-Fei Zhu, Jin-Kai Feng, Yan-Jun Xiang, Kang Wang, Li-Ping Zhou, Zong-Han Liu, Yu-Qiang Cheng, Jie Shi, Wei-Xing Guo, Shu-Qun Cheng
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The st
Externí odkaz:
https://doaj.org/article/3160f3deecbb447c921380c2af319223
Autor:
Wei‐Jun Wang, Zong‐Han Liu, Kang Wang, Hong‐Ming Yu, Yu‐Qiang Cheng, Yan‐Jun Xiang, Jin‐Kai Feng, Li‐Ping Zhou, Hong‐Kun Zhou, Wei‐Wei Pan, Wei‐Xing Guo, Jie Shi, Shu‐Qun Cheng
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11513-11524 (2023)
Abstract Background There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with
Externí odkaz:
https://doaj.org/article/6862c0cf51ad41c4a4df7fb2b3c55385
Autor:
Zong‐Han Liu, Zong‐Tao Chai, Jin‐Kai Feng, Yu‐Chao Hou, Xiu‐Ping Zhang, Zhen‐Hua Chen, Yan‐Jun Xiang, Wei‐Xing Guo, Jie Shi, Shu‐Qun Cheng
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10294-10302 (2023)
Abstract Background Early and late recurrence of hepatocellular carcinoma (HCC) have different clinical outcomes, especially for those accompanied by microvascular invasion (MVI), but the definition of early recurrence remains controversial. Therefor
Externí odkaz:
https://doaj.org/article/ecc77391e83c454b8fa8ab123bd7951a
Autor:
Li-Ming Huang, Zhen-Xin Zeng, Jun-Yi Wu, Yi-Nan Li, Jin-Xiu Wang, Yang-Kai Fu, Jia-Yi Wu, Shao-Ming Wei, Jia-Hui Lv, Wei-Zhao Chen, Rong-Fa Huang, Shu-Qun Cheng, Mao-Lin Yan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe long-term prognosis after surgery of patients with hepatocellular carcinoma (HCC) and extrahepatic bile duct tumor thrombus (Ex-BDTT) remains unknown. We aimed to identify the surgical outcomes of patients with HCC and Ex-BDTT.MethodsA
Externí odkaz:
https://doaj.org/article/ca3878e28ccc4554822b3a1531390175
Autor:
Yu Jiang Master of Engineering, Kang Wang Master of Medicine, Yu-Ran Wang Master of Engineering, Yan-Jun Xiang Master of Medicine, Zong-Han Liu Doctor of Medicine, Jin-Kai Feng Doctor of Medicine, Shu-Qun Cheng Doctor of Medicine
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Microvascular invasion of hepatocellular carcinoma is an important factor affecting tumor recurrence after liver resection and liver transplantation. There are many ways to classify microvascular invasion, however, an international consensus is urgen
Externí odkaz:
https://doaj.org/article/002b7237f3444673bdd0ff161cb088e0
Autor:
Chong-De Lu, Ya-Bo Jiang, Jin-Kai Feng, Lei Wang, Xu-Biao Wei, Bin Zhou, Xiao-Lu Lin, Wei-Xing Guo, Wan Yee Lau, Shu-Qun Cheng
Publikováno v:
Heliyon, Vol 9, Iss 9, Pp e20015- (2023)
Purpose: To compare the survival outcomes of postoperative adjuvant aspirin with surgery alone in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). Methods: From June 2013 to July 2015
Externí odkaz:
https://doaj.org/article/e71065806bc34c64a1e44787b33d9c53
Autor:
Yu-Qing Zhang, Kang Wang, Jin-Kai Feng, Lu-Yun Yuan, Chao Liang, Yan-Jun Xiang, Xu Wang, Fei-Fei Mao, Shu-Qun Cheng
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibitor (ICI), coupled with systemic chemotherapy, may enhance the clinical benefit of cancer by potentiating antitumor immunity, but its efficacy and safety are not clear in advanced intrahepatic cholangiocarcinoma (ICC
Externí odkaz:
https://doaj.org/article/20b04a6fc4454921a38cfb6e07a02fb1